Dopamine Transporter Imaging Assessment of Parkinson's Disease Progression
Annual rept. 15 Jul 1999-14 Jul 2000
YALE UNIV NEW HAVEN CT
Pagination or Media Count:
The primary goal of this study is to investigate whether sequential dopamine transporter imaging using 123Ib-CIT and SPECT, a marker of dopamine terminal integrity, will provide a quantitative biomarker of Parkinsons disease progression in subjects with early Parkisons disease during a nine month imaging interval. The subjects in this study are a subset of an NIH funded clinical trial call ELLOPA, designed to examine the effect of L-dopa on the r te of progression of Parkinsons disease. All subjects have been and will be recruited and clinically evaluated through their participation in that study. During the first grant ye r, 94 subjects recruited from 27 ELLOPA study sites have undergone their baseline 1231B-C T SPECT scan. This study will directly evaluate in vivo the rate of ongoing dopaminergic ne ronal degeneration in early Parkinsons disease, whether the rate of ongoing dopaminergic neuro al degeneration is affected by L-dopa, a potential neurotoxin, and whether the changes in imaging uptake correlate with clinical measures of disease progression. Finally, we will use 123 B-CIT and SPECT imaging to investigate the role of the dopamine transporter in the develo ment of neurotoxicity from L-dopa and related compounds.
- Anatomy and Physiology
- Medicine and Medical Research